RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-8.79%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$4.42B
AUM Growth
+$4.42B
(-10%)
Cap. Flow
+$162M
Cap. Flow
% of AUM
3.66%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
73
New
3
Increased
12
Reduced
3
Closed
14
Top Buys
| 1 |
CureVac
CVAC
|
$85.4M |
| 2 |
Vaxcyte
PCVX
|
$53.7M |
| 3 |
Mineralys Therapeutics
MLYS
|
$49.8M |
| 4 |
Pliant Therapeutics
PLRX
|
$46.9M |
| 5 |
Geron
GERN
|
$40.4M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
$83.8M |
| 2 |
Akero Therapeutics
AKRO
|
$52.6M |
| 3 |
Enliven Therapeutics
ELVN
|
$24.7M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$21.8M |
| 5 |
DALS
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
|
$15M |
Sector Composition
| 1 | Healthcare | 99.99% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
iTeos Therapeutics
ITOS
| $60.1M | 1.36% |
4,417,259
| – | – |
|
27
NewAmsterdam Pharma
NAMS
$2.71B
| $53M | 1.2% |
4,000,000
| – | – |
|
28
Viridian Therapeutics
VRDN
$1.5B
| $51.1M | 1.16% |
2,007,946
+1,127,946
| +128% | +$28.7M |
|
29
RxSight
RXST
$370M
| $50.9M | 1.15% |
3,052,796
| – | – |
|
|
30
Mineralys Therapeutics
MLYS
$1.03B
| $49.8M | 1.13% |
+3,178,476
| New | +$49.8M |
|
|
31
Pliant Therapeutics
PLRX
$101M
| $46.9M | 1.06% |
+1,762,000
| New | +$46.9M |
|
|
32
Enliven Therapeutics
ELVN
$1.2B
| $46.5M | 1.05% |
2,122,465
-1,128,259
| -35% | -$24.7M |
|
33
GH Research
GHRS
$837M
| $44.6M | 1.01% |
5,581,161
+682,788
| +14% | +$5.46M |
|
34
Acumen Pharmaceuticals
ABOS
$82.4M
| $39.7M | 0.9% |
9,770,773
| – | – |
|
|
CLYM
35
Climb Bio, Inc. Common Stock
CLYM
$151M
| $38.1M | 0.86% |
13,150,849
| – | – |
|
36
AN2 Therapeutics
ANTX
$30.1M
| $37.2M | 0.84% |
3,773,517
| – | – |
|
|
ALPN
37
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $36.2M | 0.82% |
4,688,115
+290,747
| +7% | +$2.24M |
|
38
Aclaris Therapeutics
ACRS
$209M
| $35.6M | 0.81% |
4,398,453
| – | – |
|
|
ICVX
39
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $34.6M | 0.78% |
5,963,565
| – | – |
|
40
Fulcrum Therapeutics
FULC
$351M
| $33.1M | 0.75% |
11,609,704
+2,103,779
| +22% | +$6M |
|
41
HilleVax
HLVX
$105M
| $29.1M | 0.66% |
1,760,019
| – | – |
|
42
Nkarta
NKTX
$151M
| $27.7M | 0.63% |
7,805,129
| – | – |
|
|
KNTE
43
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $26.7M | 0.6% |
4,264,144
| – | – |
|
|
NSTG
44
DELISTED
NanoString Technologies, Inc.
NSTG
| $24.3M | 0.55% |
2,457,273
+2,313,373
| +1,608% | +$22.9M |
|
45
ARS Pharmaceuticals
SPRY
$1.15B
| $19.6M | 0.44% |
3,009,678
| – | – |
|
|
46
Rocket Pharmaceuticals
RCKT
$354M
| $19.4M | 0.44% |
1,131,775
-1,275,374
| -53% | -$21.8M |
|
47
Tenaya Therapeutics
TNYA
$184M
| $17.3M | 0.39% |
6,067,483
| – | – |
|
48
Design Therapeutics
DSGN
$315M
| $17.1M | 0.39% |
2,971,231
| – | – |
|
49
Solid Biosciences
SLDB
$427M
| $16.2M | 0.37% |
3,426,286
| – | – |
|
50
Werewolf Therapeutics
HOWL
$59.9M
| $16M | 0.36% |
6,144,881
+1,853,000
| +43% | +$4.82M |
|